Changes in Beneficial Ownership · 4
Glaukos Corporation
GKOSNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-11-18
- Issuer
- GLAUKOS Corp
- Issuer CIK
- 0001192448
- Trading symbol
- GKOS
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Burns Thomas William
- Reporting owner CIK
- 0001644557
- Relationship
- Director · Officer
- Officer title
- CHAIRMAN & CEO
- Address
- C/O GLAUKOS CORPORATION, ONE GLAUKOS WAY, ALISO VIEJO, CA, 92656
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-11-18 | M · Form 4 | 180,000 | A | 45.71 | 245,060[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 40,450 | D | 232.61[F3] | 204,610[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 19,288 | D | 233.78[F4] | 185,322[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 25,558 | D | 234.74[F5] | 159,764[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 4,285 | D | 235.46[F6] | 155,479[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 15,689 | D | 237.29[F7] | 139,790[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 21,601 | D | 237.99[F8] | 118,189[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 10,096 | D | 239.27[F9] | 108,093[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 10,942 | D | 240.06[F10] | 97,151[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 5,421 | D | 241.14[F11] | 91,730[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 3,390 | D | 242.46[F12] | 88,340[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 6,919 | D | 243.02[F13] | 81,421[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 15,040 | D | 244.18[F14] | 66,381[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 1,087 | D | 245.31[F15] | 65,294[F1] | D |
| Common Stock | 2026-11-18 | S · Form 4[F2] | 234 | D | 245.90[F16] | 65,060[F1] | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 1,141,593 | I | Through the Burns Family Trust |
| Common Stock | 238,107 | I | Through the Burns Annuity Trust |
| Common Stock | 120,000 | I | Through the Burns Charitable Remainder Trust |
| Common Stock | 100,000 | I | Through the Thomas W. Burns Irrevocable Trust |
| Common Stock | 100,000 | I | Through the Janet M. Burns Irrevocable Trust |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 45.71 | 2026-11-18 | M · Form 4 | 180,000[F17] | D | 0 | [F18] | 2027-03-15 | Common Stock | 180,000 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Includes 48,673 restricted stock units that have not yet vested or been delivered to the Reporting Person.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14↩ 15
- F2
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2026 with respect to options that expire on March 15, 2027.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14
- F3
- This transaction was executed in multiple trades at prices ranging from $232.17 to $233.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F4
- This transaction was executed in multiple trades at prices ranging from $233.22 to $234.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F5
- This transaction was executed in multiple trades at prices ranging from $234.23 to $235.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F6
- This transaction was executed in multiple trades at prices ranging from $235.24 to $235.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F7
- This transaction was executed in multiple trades at prices ranging from $236.60 to $237.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F8
- This transaction was executed in multiple trades at prices ranging from $237.61 to $238.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F9
- This transaction was executed in multiple trades at prices ranging from $238.64 to 239.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F10
- This transaction was executed in multiple trades at prices ranging from $239.66 to $240.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F11
- This transaction was executed in multiple trades at prices ranging from $240.68 to $241.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F12
- This transaction was executed in multiple trades at prices ranging from $241.70 to $242.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F13
- This transaction was executed in multiple trades at prices ranging from $242.72 to $243.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F14
- This transaction was executed in multiple trades at prices ranging from $243.74 to $244.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F15
- This transaction was executed in multiple trades at prices ranging from $244.76 to $245.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F16
- This transaction was executed in multiple trades at prices ranging from $245.81 to $246.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F17
- The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2026 with respect to options that expire on March 15, 2027.↩ 1
- F18
- These options vest over four years from the grant date, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years.↩ 1
Signature 1
- Signed
- Diana Scherer, Attorney-in-Fact
- Date
- 2026-11-20
Company context
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel,